$RARX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Ra Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Ra Pharmaceuticals, Inc.. Get notifications about new insider transactions in Ra Pharmaceuticals, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Sell | D | 0.00 | 6,135,234 | 0 | 0 | 6.1 M to 0 (-100.00 %) |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Mathers Edward T | Director | Option Exercise | D | 19.88 | 15,000 | 298,200 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Mathers Edward T | Director | Option Exercise | D | 9.90 | 15,000 | 148,500 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Mathers Edward T | Director | Option Exercise | D | 22.37 | 15,000 | 335,550 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Treco Douglas A | President and CEO | Option Exercise | D | 0.00 | 20,833 | 0 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Treco Douglas A | President and CEO | Option Exercise | D | 21.00 | 311,000 | 6,531,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Treco Douglas A | President and CEO | Option Exercise | D | 7.33 | 125,000 | 916,250 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Treco Douglas A | President and CEO | Option Exercise | D | 16.64 | 225,000 | 3,744,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Treco Douglas A | President and CEO | Option Exercise | D | 5.60 | 164,285 | 919,996 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Treco Douglas A | President and CEO | Option Exercise | D | 2.87 | 241,460 | 692,990 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Treco Douglas A | President and CEO | Option Exercise | D | 2.87 | 139,371 | 399,995 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Treco Douglas A | President and CEO | Sell | D | 48.00 | 234,707 | 11,265,936 | 0 | 234.7 K to 0 (-100.00 %) |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 0.00 | 10,416 | 0 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 21.00 | 133,000 | 2,793,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 7.33 | 62,500 | 458,125 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 16.64 | 112,500 | 1,872,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 5.60 | 28,571 | 159,998 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 2.87 | 92,283 | 264,852 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Option Exercise | D | 2.87 | 115,572 | 331,692 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Lubner David Charles | Executive VP and CF ... | Sell | D | 48.00 | 15,622 | 749,856 | 0 | 15.6 K to 0 (-100.00 %) |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Option Exercise | D | 0.00 | 4,375 | 0 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Option Exercise | D | 21.00 | 107,000 | 2,247,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Option Exercise | D | 7.33 | 26,250 | 192,413 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Option Exercise | D | 16.64 | 60,000 | 998,400 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Option Exercise | D | 5.60 | 31,428 | 175,997 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Option Exercise | D | 2.87 | 30,000 | 86,100 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Option Exercise | D | 2.87 | 14,285 | 40,998 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Option Exercise | D | 0.84 | 2,857 | 2,400 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Sell | D | 48.00 | 2,973 | 142,704 | 0 | 3 K to 0 (-100.00 %) |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | D | 0.00 | 9,166 | 0 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | D | 21.00 | 107,000 | 2,247,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | D | 7.33 | 55,000 | 403,150 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | D | 16.64 | 67,500 | 1,123,200 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | D | 5.60 | 25,000 | 140,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | D | 2.87 | 26,422 | 75,831 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | D | 2.87 | 46,434 | 133,266 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Sell | D | 48.00 | 12,595 | 604,560 | 0 | 12.6 K to 0 (-100.00 %) |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | D | 0.00 | 10,416 | 0 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | D | 21.00 | 133,000 | 2,793,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | D | 7.33 | 62,500 | 458,125 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | D | 16.64 | 90,000 | 1,497,600 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | D | 5.60 | 73,654 | 412,462 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | D | 5.60 | 11,110 | 62,216 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | D | 48.00 | 14,492 | 695,616 | 0 | 14.5 K to 0 (-100.00 %) |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Cumbo Alexander | Director | Option Exercise | D | 12.99 | 25,000 | 324,750 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Cumbo Alexander | Director | Option Exercise | D | 19.88 | 15,000 | 298,200 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | PEARSON TIMOTHY R | Director | Option Exercise | D | 19.88 | 15,000 | 298,200 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | PEARSON TIMOTHY R | Director | Option Exercise | D | 9.90 | 15,000 | 148,500 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | PEARSON TIMOTHY R | Director | Option Exercise | D | 22.37 | 15,000 | 335,550 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | PEARSON TIMOTHY R | Director | Option Exercise | D | 2.87 | 22,857 | 65,600 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | King John C | Chief Commercial Of ... | Option Exercise | D | 0.00 | 30,658 | 0 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | King John C | Chief Commercial Of ... | Option Exercise | D | 21.00 | 107,000 | 2,247,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | King John C | Chief Commercial Of ... | Option Exercise | D | 6.20 | 190,000 | 1,178,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | King John C | Chief Commercial Of ... | Sell | D | 48.00 | 10,823 | 519,504 | 0 | 10.8 K to 0 (-100.00 %) |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Option Exercise | D | 19.88 | 15,000 | 298,200 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Option Exercise | D | 9.90 | 15,000 | 148,500 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Option Exercise | D | 22.37 | 15,000 | 335,550 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Sell | D | 48.00 | 4,858,260 | 233,196,480 | 0 | 4.9 M to 0 (-100.00 %) |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Heft Robert | Director | Option Exercise | D | 19.88 | 15,000 | 298,200 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Heft Robert | Director | Option Exercise | D | 9.90 | 15,000 | 148,500 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Heft Robert | Director | Option Exercise | D | 22.37 | 15,000 | 335,550 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Heft Robert | Director | Option Exercise | D | 2.87 | 22,857 | 65,600 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | RA CAPITAL MANAGEMENT, L.P. | Director | Sell | D | 48.00 | 4,858,260 | 233,196,480 | 0 | 4.9 M to 0 (-100.00 %) |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Brennan Aoife | Director | Option Exercise | D | 16.36 | 25,000 | 409,000 | 0 | |
| Apr 03 2020 | RARX | Ra Pharmaceuticals ... | Brennan Aoife | Director | Option Exercise | D | 19.88 | 15,000 | 298,200 | 0 | |
| Mar 18 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Sell | S | 44.25 | 2,288 | 101,244 | 0 | 2.3 K to 0 (-100.00 %) |
| Mar 18 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 73,654 | |
| Mar 18 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 11,110 | |
| Mar 18 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 45.16 | 10,595 | 478,521 | 7,132 | 17.7 K to 7.1 K (-59.77 %) |
| Mar 18 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Mar 18 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Feb 20 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 82,860 | |
| Feb 20 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 12,499 | |
| Feb 20 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 46.61 | 10,595 | 493,850 | 7,132 | 17.7 K to 7.1 K (-59.77 %) |
| Feb 20 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Feb 20 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Jan 21 2020 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Sell | S | 47.02 | 2,285 | 107,441 | 2,288 | 4.6 K to 2.3 K (-49.97 %) |
| Jan 16 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 92,066 | |
| Jan 16 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 13,888 | |
| Jan 16 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 46.95 | 10,595 | 497,441 | 7,132 | 17.7 K to 7.1 K (-59.77 %) |
| Jan 16 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Jan 16 2020 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Dec 18 2019 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Sell | S | 47.08 | 2,285 | 107,568 | 4,573 | 6.9 K to 4.6 K (-33.32 %) |
| Dec 18 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | M | 2.87 | 10,000 | 28,700 | 46,142 | |
| Dec 18 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Sell | S | 47.08 | 10,000 | 470,821 | 6,234 | 16.2 K to 6.2 K (-61.60 %) |
| Dec 18 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Buy | M | 2.87 | 10,000 | 28,700 | 16,234 | 6.2 K to 16.2 K (+160.41 %) |
| Dec 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 101,272 | |
| Dec 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 15,277 | |
| Dec 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 47.23 | 10,595 | 500,351 | 7,132 | 17.7 K to 7.1 K (-59.77 %) |
| Dec 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Dec 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Nov 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 110,478 | |
| Nov 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 16,666 | |
| Nov 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 46.66 | 10,595 | 494,319 | 7,132 | 17.7 K to 7.1 K (-59.77 %) |
| Nov 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Nov 18 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Nov 18 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | M | 2.87 | 10,000 | 28,700 | 56,142 | |
| Nov 18 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Sell | S | 46.68 | 10,000 | 466,808 | 6,234 | 16.2 K to 6.2 K (-61.60 %) |
| Nov 18 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Buy | M | 2.87 | 10,000 | 28,700 | 16,234 | 6.2 K to 16.2 K (+160.41 %) |
| Oct 17 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | M | 2.87 | 10,000 | 28,700 | 66,142 | |
| Oct 17 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Sell | S | 46.87 | 10,000 | 468,726 | 6,234 | 16.2 K to 6.2 K (-61.60 %) |
| Oct 17 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Buy | M | 2.87 | 10,000 | 28,700 | 16,234 | 6.2 K to 16.2 K (+160.41 %) |
| Oct 17 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 119,684 | |
| Oct 17 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 18,055 | |
| Oct 17 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 46.89 | 10,595 | 496,769 | 7,132 | 17.7 K to 7.1 K (-59.77 %) |
| Oct 17 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Oct 17 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Oct 17 2019 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Sell | S | 46.70 | 2,285 | 106,710 | 6,858 | 9.1 K to 6.9 K (-24.99 %) |
| Sep 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 128,890 | |
| Sep 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 19,444 | |
| Sep 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 25.26 | 10,595 | 267,675 | 7,132 | 17.7 K to 7.1 K (-59.77 %) |
| Sep 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Sep 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Sep 16 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | M | 2.87 | 10,000 | 28,700 | 76,142 | |
| Sep 16 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Sell | S | 25.41 | 10,000 | 254,050 | 6,234 | 16.2 K to 6.2 K (-61.60 %) |
| Sep 16 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Buy | M | 2.87 | 10,000 | 28,700 | 16,234 | 6.2 K to 16.2 K (+160.41 %) |
| Aug 27 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | M | 2.87 | 10,000 | 28,700 | 86,142 | |
| Aug 27 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Sell | S | 27.77 | 10,000 | 277,703 | 6,234 | 16.2 K to 6.2 K (-61.60 %) |
| Aug 27 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Buy | M | 2.87 | 10,000 | 28,700 | 16,234 | 6.2 K to 16.2 K (+160.41 %) |
| Aug 27 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 138,096 | |
| Aug 27 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 20,833 | |
| Aug 27 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 27.77 | 10,595 | 294,226 | 7,132 | 17.7 K to 7.1 K (-59.77 %) |
| Aug 27 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Aug 27 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Aug 27 2019 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Sell | S | 27.89 | 2,285 | 63,740 | 9,143 | 11.4 K to 9.1 K (-19.99 %) |
| Jul 18 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | M | 2.87 | 10,000 | 28,700 | 96,142 | |
| Jul 18 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Sell | S | 32.95 | 10,000 | 329,479 | 6,234 | 16.2 K to 6.2 K (-61.60 %) |
| Jul 18 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Buy | M | 2.87 | 10,000 | 28,700 | 16,234 | 6.2 K to 16.2 K (+160.41 %) |
| Jul 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 147,302 | |
| Jul 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 22,222 | |
| Jul 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 33.29 | 4,216 | 140,338 | 7,132 | 11.3 K to 7.1 K (-37.15 %) |
| Jul 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 32.97 | 6,379 | 210,309 | 11,348 | 17.7 K to 11.3 K (-35.98 %) |
| Jul 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Jul 16 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Jun 25 2019 | RARX | Ra Pharmaceuticals ... | Ricardo Alonso | See Remarks | Sell | S | 23.72 | 2,857 | 67,782 | 11,428 | 14.3 K to 11.4 K (-20.00 %) |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Option Exercise | M | 2.87 | 10,000 | 28,700 | 106,142 | |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Sell | S | 23.09 | 414 | 9,560 | 6,234 | 6.6 K to 6.2 K (-6.23 %) |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Sell | S | 22.21 | 9,586 | 212,908 | 6,648 | 16.2 K to 6.6 K (-59.05 %) |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Read Simon | Chief Scientific Of ... | Buy | M | 2.87 | 10,000 | 28,700 | 16,234 | 6.2 K to 16.2 K (+160.41 %) |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 9,206 | 51,554 | 156,508 | |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Option Exercise | M | 5.60 | 1,389 | 7,778 | 23,611 | |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 22.04 | 7,184 | 158,363 | 7,132 | 14.3 K to 7.1 K (-50.18 %) |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Sell | S | 21.41 | 3,411 | 73,021 | 14,316 | 17.7 K to 14.3 K (-19.24 %) |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 9,206 | 51,554 | 17,727 | 8.5 K to 17.7 K (+108.04 %) |
| Jun 19 2019 | RARX | Ra Pharmaceuticals ... | Farzaneh-Far Ramin | Chief Medical Offic ... | Buy | M | 5.60 | 1,389 | 7,778 | 8,521 | 7.1 K to 8.5 K (+19.48 %) |
| Jun 13 2019 | RARX | Ra Pharmaceuticals ... | Shah Rajeev M. | Director | Option Exercise | A | 19.88 | 15,000 | 298,200 | 15,000 | |
| Jun 13 2019 | RARX | Ra Pharmaceuticals ... | Cumbo Alexander | Director | Option Exercise | A | 19.88 | 15,000 | 298,200 | 15,000 | |
| Jun 13 2019 | RARX | Ra Pharmaceuticals ... | PEARSON TIMOTHY R | Director | Option Exercise | A | 19.88 | 15,000 | 298,200 | 15,000 | |
| Jun 13 2019 | RARX | Ra Pharmaceuticals ... | Brennan Aoife | Director | Option Exercise | A | 19.88 | 15,000 | 298,200 | 15,000 | |
| Jun 13 2019 | RARX | Ra Pharmaceuticals ... | Heft Robert | Director | Option Exercise | A | 19.88 | 15,000 | 298,200 | 15,000 |